U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.20 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.65 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +0.19 (+0.29%)
     
  • Gold

    1,698.20
    -0.30 (-0.02%)
     
  • Silver

    25.30
    +0.01 (+0.03%)
     
  • EUR/USD

    1.1927
    -0.0051 (-0.43%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3856
    -0.0038 (-0.28%)
     
  • USD/JPY

    108.3950
    +0.4190 (+0.39%)
     
  • BTC-USD

    50,616.21
    +1,994.35 (+4.10%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

Novo Nordisk Raises Sales & Operating Profit Outlook for 2020

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Novo Nordisk A/S NVO announced preliminary third-quarter 2020 sales and operating profit results and raised 2020 sales and operating profit outlook at constant exchange rates (CER).

In the third quarter of 2020, the company’s sales increased 7% and operating profit grew 7%, both at CER. The growth reflects that the negative impact due to COVID-19 was lesser than expected. Sales were positively impacted by inventory changes at the wholesale level in the United States. 

Due to a lesser-than-expected impact of COVID-19 and the underlying market demand, the company raised its sales and operating profit outlook for 2020. It now expects sales growth in the range of 5-8%,up from the previous expectation of 3-6%. The company also expects operating profit guidance in the range of 5-8%, up from the prior expectation of 2-5%. The outlook is based on a number of assumptions related to the severity and duration of the impacts ofCOVID-19 along with other factors.

Shares of the company have gained 23.1% against the industry’s 0.3% decline.

Novo Nordisk has a strong presence in the Diabetes care market with one of the broadest diabetes portfolios in the industry. The company has improved its global diabetes value market share over the last 12 months from 28.2% to 29%, driven by an improved global insulin market share and the expansion of the GLP-1 segment as well as market share.

 

Novo Nordisk AS Price

Novo Nordisk AS Price
Novo Nordisk AS Price

Novo Nordisk AS price | Novo Nordisk AS Quote

Zacks Rank &Stocks to Consider

Novo Nordisk currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the healthcare sector include Emergent Biosolutions Inc. EBS, Amicus Therapeutics Inc. FOLD and AVEO Pharmaceuticals Inc. AVEO. While Emergentsports a Zacks Rank #1 (Strong Buy), Amicus and AVEO carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Emergent’s earnings estimates have increased from $4.03 to $6.61 for 2020 and from $5.07 to $8.42 for 2021 over the past 90 days. Shares of the company have increased 104.7% year to date.

FOLD’s loss per share estimates have narrowed from $1.08 to $1.01 for 2020 and from 67 cents to 61 cents for 2021 over the past 60 days. Shares of the company have increased 53% year to date.

AVEO’s loss per share estimates have narrowed from $1.68 to $1.25 for 2020 and from $1.71 to $1.22 for 2021 over the past 60 days. Shares of the company have increased 5.8% year to date.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year. These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Novo Nordisk AS (NVO) : Free Stock Analysis Report
 
AVEO Pharmaceuticals, Inc. (AVEO) : Free Stock Analysis Report
 
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
 
Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research